Objective:
The objective of this specific cooperative agreement is to use reasonable commercial efforts to construct, produce, and test a series of replication-defective recombinant adenovirus serotype 5 (rAd5) based vector containing an expression cassette for i) type I interferon cytokines, ii) type II interferon cytokines, iii) luciferase reporter gene, iv) GFP reporter gene, and v) FMDV serotype empty capsids, as part of the PIADC FMD vaccine and immunomodulator research program.

Approach:
Using GenVec's (GNVC) AdVaccine platform technology, select an optimal rAd5 vector for high expression of the pIFN-alpha in bovine and swine established cell lines. Using standard operating protocols, construct a GV-11 based vector expressing pIFN-alpha using GNVC proprietary vectors and cell lines. The GNVAC proprietary system will result in the elimination or significant reduction in the generation of wild-type Ad5 during virus replication. A select set of GNVC rAd5 vectors previously optimized for expression of secreted transgene products will be tested for in vitro expression. Results will be used to identify the rAd5 vector for production of CsCl purified GV-11/pIFN-alpha recombinant virus for a pilot efficacy trial in swine and/or cattle. Results from this work may be useful for future applications related to construction, production and testing of a rAd5 vector containing an expression cassette for the FMDV serotype A24 P1 capsid. In addition, GenVec., will produce and send to PIADC in-vitro and in-vivo evaluation of CsC1 purified vectors (as detailed in the Statement of Work.) Construction of one or more stable recombinant vectors will be done by molecular characterization. These vectors will then be sent to PIADC for in-vitro and in-vivo evaulation.